Free summer meals available for Colorado children aged 18 and younger
GRAND JUNCTION, Colo. (KREX) — On Tuesday, the Colorado Department of Education (CDE) announced that 635 summer meal sites are open throughout Colorado to provide free meals to children aged 18 and younger. Out of those 635 locations, 16 are open in Grand Junction.
In Grand Junction, these locations include: Chipeta Elementary School, Dos Rios Elementary School, Pear Park Elementary School, Pomona Elementary School, Tope Elementary School, Bookcliff Middle School, Orchard Mesa Middle School, Grand Junction High School, CMU Tech, Candlewood Park, Clifton Community Center, Dual Immersion Academy School, EUREKA! Science Museum, Kimwood Park, Lincoln Park and Mesa Avenue Park.
Parents, families and community members can learn more about locations and hours at www.kidsfoodfinder.org.
No registration, identification, or proof of income or enrollment is required to access summer meals. All meals served meet USDA nutrition guidelines.
The Colorado Department of Education's School Nutrition Unit, in partnership with community-based program sponsors, runs the Summer Meal Program and provided over 1.9 million meals to Colorado youth last year. The U.S. Department of Agriculture funds the program.
CDE is currently working with 82 community organizations to run the 635 meal sites across the state. In rural areas, a to-go or delivery option for meals may be offered. Local schools, nonprofits, government agencies, camps, faith- or community-based organizations can join the program to provide new meal sites at any time throughout the summer.
'Many Colorado children rely on their schools for access to food, and our Summer Meals Program provides a critical resource for children and families during the summer months. We are grateful to our 83 community partners for stepping up to serve them,' said Colorado Education Commissioner Susana Córdova.
In addition to the Summer Meals Program, children and teens can get free meals over the summer through the Lunch Lizard. The mobile summer food program operates across Mesa County and served its first set of children on Monday in Fruita.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 hours ago
- Yahoo
Innovent's IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) Receives Second NMPA Breakthrough Therapy Designation for Immuno-resistant Squamous Non-Small Cell Lung Cancer
SAN FRANCISCO and SUZHOU, China, June 4, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology, and other major diseases, announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted a second Breakthrough Therapy Designation (BTD) to its first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein, IBI363, for the treatment of unresectable, locally advanced, or metastatic squamous non-small cell lung cancer (sqNSCLC) that has progressed following anti-PD-(L)1 immunotherapy and platinum-based chemotherapy. To date, IBI363 has received BTDs from China's NMPA CDE and Fast Track Designations (FTDs) from the U.S. FDA for two indications—sqNSCLC and melanoma. The latest BTD further advances IBI363's potential in addressing immunotherapy resistance and cold tumor challenges. The latest data from the Phase 1 clinical study of IBI363 in subjects with squamous non-small cell lung cancer (sqNSCLC) who previously received immunotherapy were reported in an oral presentation at the 2025 ASCO Annual Meeting. Manageable safety, encouraging efficacy, and long-term survival benefits were observed in both immunotherapy-resistant squamous non-small cell lung cancer and wild-type lung adenocarcinoma, offering new therapeutic hope for immunotherapy-resistant patients. At this year's ASCO conference, IBI363 presented breakthrough clinical findings in three immunotherapy-resistant and cold tumor types: non-small cell lung cancer, colorectal cancer, and melanoma, garnering significant attention. Dr. Hui Zhou, Senior Vice President of Innovent, stated, "IBI363 could potentially be a promising next-generation IO agent by combining dual mechanisms—PD-1 blockade and IL-2-driven tumor-specific T-cell populations expansion—thus reshape the tumor microenvironment. Recent regulatory milestones, including multiple FTDs and BTDs, underscore its clinical value in addressing unmet needs. We are accelerating IBI363's global development across multiple tumor types: the first registrational study in acral and mucosal melanoma, a head-to-head trial against pembrolizumab, has already been initiated. We will communicate with regulatory authorities about additional registrational clinical trials for lung cancer and colorectal cancer, bringing innovation therapies at the forefront of immunotherapy to benefit global patients." NMPA Breakthrough Therapy Designation is intended to facilitate and expedite the development and review of investigational drugs for serious diseases or conditions when preliminary clinical evidence indicates substantial improvement over current therapies. BTD qualifies a drug candidate for accelerated review by the CDE and provides the sponsor with timely advice and communication to expedite the approval process, helping to address the unmet clinical needs of patients more swiftly. About Squamous Non-Small Cell Lung Cancer (sqNSCLC) Lung cancer is the most common and deadliest malignancy worldwide, including in China[1], posing a significant public health challenge. Non-small cell lung cancer (NSCLC) accounts for more than 80% of all lung cancer cases[2], with squamous cell carcinoma being one of its two major subtypes[2]. In recent years, immune checkpoint inhibitors have transformed the treatment landscape for NSCLC. However, for patients with NSCLC who have failed immunotherapy and lack driver gene mutations, there remains a significant and urgent unmet need for effective treatment options. The standard second- or third-line treatment, docetaxel, offers limited efficacy, with a median progression-free survival (PFS) of less than four months[3],[4]. While antibody-drug conjugates (ADCs) have shown promise, two large Phase 3 studies in squamous NSCLC have yet to demonstrate satisfactory efficacy[3],[4]. About IBI363 (First-in-class PD-1/IL-2α-bias bispecific antibody fusion protein) IBI363 is a first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein independently developed by Innovent Biologics. It functions by both blocking the PD-1/PD-L1 pathway and activating the IL-2 pathway. The IL-2 arm of IBI363 is designed to maintain its affinity for IL-2Rα while reducing binding to IL-2Rβ and IL-2Rγ, thereby minimizing toxicity. The PD-1 binding arm not only blocks PD-1 but also selectively delivers IL-2. This approach targets and activates tumor-specific T cells that express both PD-1 and IL-2α, leading to more precise and effective activation of this T cell subpopulation. IBI363 has demonstrated robust antitumor activity in various tumor-bearing pharmacological models, but also showed outstanding efficacy in PD-1 resistance and metastasis models. At this year's ASCO conference, IBI363 presented breakthrough clinical findings in three immunotherapy-resistant and cold tumor types: non-small cell lung cancer, colorectal cancer, and melanoma, garnering significant attention. In response to urgent clinical needs, Innovent is conducting clinical studies in China, the United States and Australia to further explore the efficacy and safety of IBI363 in various tumor indications, including immune-resistant, cold tumors, and front-line treatments. The first pivotal trial of IBI363 was initiated in 2025 for unresectable locally advanced or metastatic mucosal or acral melanoma who have not received prior systemic therapy. IBI363 has received two fast track designations (FTD) from the U.S. FDA and two breakthrough designations (BTD) from the China NMPA, for the treatment of squamous non-small cell lung cancer and melanoma, respectively. About Innovent Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 15 products in the market. It has 3 new drug applications (NDA) under regulatory review, 4 assets in Phase III or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center. Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit or follow Innovent on Facebook and LinkedIn. Statement: 1) Innovent does not recommend the use of any unapproved drug (s)/indication (s). 2) Ramucirumab (Cyramza) and Selpercatinib (Retsevmo) and Pirtobrutinib (Jaypirca) were developed by Eli Lilly and Company. Forward-Looking Statements This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent's competitive environment and political, economic, legal and social conditions. Innovent, the Directors and the employees of Innovent assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect. References: 1 Globocan 2022 (version 1.1) - 08.02.2024 2 NCCN guidelines (NSCLC, version 3.2025) 3 J Clin Oncol . 2025 Jan 20;43(3):260-272. doi: 10.1200/JCO-24-01544. 4 J Clin Oncol . 2024 Aug 20;42(24):2860-2872. doi: 10.1200/JCO.24.00733. View original content: SOURCE Innovent Biologics Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Yahoo
JUCO World Series bracket, seedings released by NJCAA
GRAND JUNCTION, Colo. (KREX) — With all 10 Junior College World Series teams set to begin practicing in Grand Junction Wednesday, the NJCAA released the full seedings Tuesday. The 2025 Alpine Bank JUCO World Series will begin Saturday 9 a.m. at Suplizio Field with a battle between two teams who were here a year ago: Johnson County vs. McLennan. Advertisement Here are the official seedings for the tournament: Walters State 55-6-1 Blinn 46-13 Florida SouthWestern 44-15 Johnson County 51-11 Shelton State 48-12 Florence Darlington Tech 51-10 McLennan 45-16 Salt Lake CC 43-10 Lake Land 42-19 Eastern Oklahoma State 31-25 Here is the official bracket, available at Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed. For the latest news, weather, sports, and streaming video, head to
Yahoo
2 days ago
- Yahoo
Grand Junction Bomb Squad determines unknown liquid in jars safe
GRAND JUNCTION, Colo. (KREX) — On Tuesday, at approximately 2:20 p.m., the Grand Junction Police Department (GJPD) responded to a report of unknown liquids found in jars in the 2500 block of Ouray Avenue. The reporting party stated that she had discovered several jars with an unknown liquid in a residential garage. Technicians with the Grand Junction Bomb Squad were called to assist. Bomb technicians with the Grand Junction Fire Department HazMat Technicians tested the substances and confirmed that the jars held no threat to the community. There was no evidence of any Molotov cocktail materials found during the incident. All of the substances will be taken to the hazardous waste facility. Recognizing the concern following the recent attack in Boulder, the Grand Junction Police Department takes reports of all suspicious activity seriously. GJPD encourages Grand Junction residents to be vigilant and call 911 for any unusual activity. The GJPD believes this incident to be isolated with no ongoing threat to the community. WesternSlopeNow will update this story if it develops. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
